Press releases

You will be able to find all of our recent and archived news announcements. Our press releases are intended for business journalists and analysts/investors.

ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV

ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 495 treatment-naïve women living with HIV.

Read more - ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV Read more